Skip to main content
. Author manuscript; available in PMC: 2011 Jun 8.
Published in final edited form as: Brain Res. 2010 Apr 8;1336:78–88. doi: 10.1016/j.brainres.2010.03.098

Figure 4.

Figure 4

Plasma corticosterone levels 20 minutes after initial maze exposure. The GR agonist RU28362 delivered bilaterally to the central nucleus of the amygdala (CeA) increases plasma corticosterone 20 minutes following the initiation of elevated plus maze (#). Peripheral treatment with the ERβ agonist S-DPN decreases plasma corticosterone following the elevated plus maze and blocks the augmentation of plasma corticosterone seen with RU28362 administration to the CeA (*). Data are represented as mean ± SEM; n = 6–7 animals per treatment group. *, indicates significant difference (P < 0.05) compared with animals implanted with blank pellets and vehicle treated (controls); #, indicates significant effect of peripheral treatment in groups with same central treatment.